Overview

Useful For
This serum test is a comprehensive profile that provides information regarding mitochondrial and peroxisomal fatty acid metabolism, and the patient's nutritional status.

- Monitoring patients undergoing diet therapy for mitochondrial or peroxisomal disorders (possibly inducing essential fatty acid deficiency in response to restricted fat intake)
- Monitoring treatment of essential fatty acid deficiency
- Monitoring the response to provocative tests (fasting tests, loading tests)

Genetics Test Information
This test is a comprehensive profile that provides information regarding mitochondrial and peroxisomal fatty acid metabolism, and the patient's nutritional status.

While providing useful information regarding very long chain fatty acids, this test is not the recommended initial screening test for evaluating patients with possible peroxisomal disorders, single-enzyme defects of peroxisomal metabolism such as X-linked adrenoleukodystrophy, or peroxisomal biogenesis disorders (Zellweger syndrome spectrum). For this purpose POXP / Fatty Acid Profile, Peroxisomal (C22-C26), Plasma or POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum is preferred.

Method Name
Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis

NY State Available
Yes

Specimen

Specimen Type
Serum

Necessary Information
1. Patient's age is required.
2. Include information regarding treatment, family history, and tentative diagnosis.

Specimen Required
Patient Preparation:
1. Patient should fast overnight (12-14 hours).
2. Patient must not consume any alcohol for 24 hours before the specimen is drawn.

Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Spin down within 45 minutes of draw.

Forms
If not ordering electronically, complete, print, and send an Inborn Errors of Metabolism Test Request (T798) with the specimen.

Specimen Minimum Volume
0.15 mL

Reject Due To

<table>
<thead>
<tr>
<th>Condition</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td>OK</td>
</tr>
<tr>
<td>Gross lipemia</td>
<td>Reject</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>OK</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Frozen (preferred)</td>
<td>92 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td>72 hours</td>
<td></td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information
Fatty Acid Deficiency/Excess:

Fats are important sources of energy for tissues and for the function and integrity of cellular membranes. Deficiencies are commonly caused by inadequate dietary intake of lipids due to an unbalanced diet, long-term parenteral nutrition, or by intestinal malabsorption. Linoleic acid, an omega-6 fatty acid, and alpha-linolenic acid, an omega-3 fatty acid, are considered essential fatty acids in that they cannot be made by the body and are essential components of the diet.

The major clinical manifestations associated with essential fatty acid deficiency (EFAD) include dermatitis, increased water permeability of the skin, increased susceptibility to infection, and impaired wound healing. Biochemical abnormalities may be detected before the onset of recognizable clinical manifestations. EFAD can be detected by diminished levels of the essential fatty acids linoleic acid and alpha-linolenic acid, as well as by increases in the triene:tetraene ratio.

Excess dietary fatty acids have been linked to the onset of cardiovascular disease. Elevated levels of linoleic acid can contribute to overproduction of the proinflammatory 2-series local hormones.
Fatty Acid Oxidation (FAO) Disorders:

Mitochondrial beta-oxidation is the main source of energy to skeletal and heart muscle during periods of fasting. When the body's supply of glucose is depleted, fatty acids are mobilized from adipose tissue and converted to ketone bodies through a series of steps providing an alternate source of energy. Deficient enzymes at any step in this pathway prevent the production of energy during periods of physiologic stress such as fasting or intercurrent illness.

The major clinical manifestations associated with FAO disorders include hypoketotic hypoglycemia, liver disease and failure, skeletal myopathy, dilated/hypertrophic cardiomyopathy, and sudden unexpected death in early life. Signs and symptoms may vary greatly in severity, combination, and age of presentation. Life-threatening episodes of metabolic decompensation frequently occur after periods of inadequate calorie intake or intercurrent illness. When properly diagnosed, patients with FAO disorders respond favorably to fasting avoidance, diet therapy, and aggressive treatment of intercurrent illnesses, with significant reduction of morbidity and mortality.

Disease-specific characteristic patterns of metabolites from FAO disorders are detectable in blood, bile, urine, and cultured fibroblasts of living and many deceased individuals. Quantitative determination of C8-C18 fatty acids is an important element of the work-up and differential diagnosis of candidate patients. Fatty acid profiling can detect quantitatively modest, but nevertheless significant, abnormalities even when patients are asymptomatic and under dietary treatment. Confirmatory testing via the FAO / Fatty Acid Oxidation Probe Assay, Fibroblast Culture and molecular analysis are also available for many of the FAO disorders at Mayo Clinic Laboratories.

Peroxisomal Disorders:

Peroxisomes are organelles present in all human cells except mature erythrocytes. They carry out essential metabolic functions including beta-oxidation of very long-chain fatty acids (VLCFA), alpha-oxidation of phytanic acid, and biosynthesis of plasmalogen and bile acids. Peroxisomal disorders include disorders of peroxisomal biogenesis with defective assembly of the entire organelle and single peroxisomal enzyme/transporter defects where the organelle is intact but a specific function is disrupted. Peroxisomal beta-oxidation of VLCFA is impaired in all disorders of peroxisomal biogenesis and in selected single enzyme deficiencies, particularly X-linked adrenoleukodystrophy, resulting in elevated concentrations of VLCFA in serum or plasma. POXP / Fatty Acid Profile, Peroxisomal (C22-C26), Plasma or POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum is the preferred screening test for evaluating patients with possible peroxisomal disorders, single-enzyme defects of peroxisomal metabolism such as X-linked adrenoleukodystrophy, or peroxisomal biogenesis disorders (Zellweger syndrome spectrum). Confirmatory testing for X-linked adrenoleukodystrophy (XALDZ / X-Linked Adrenoleukodystrophy, Full Gene Analysis) via molecular genetic analysis is available at Mayo Clinic Laboratories.

**Reference Values**

**Octanoic Acid, C8:0**

<1 year: 7-63 nmol/mL

1-17 years: 9-41 nmol/mL

> or =18 years: 8-47 nmol/mL

**Decenoic Acid, C10:1**

<1 year: 0.8-4.8 nmol/mL

1-17 years: 1.6-6.6 nmol/mL
Test Definition: FAPCP
Fatty Acid Profile, Comprehensive,S

> or = 18 years: 1.8-5.0 nmol/mL

Decanoic Acid, C10:0

<1 year: 2-62 nmol/mL
1-17 years: 3-25 nmol/mL
> or = 18 years: 2-18 nmol/mL

Lauroleic Acid, C12:1

<1 year: 0.6-4.8 nmol/mL
1-17 years: 1.3-5.8 nmol/mL
> or = 18 years: 1.4-6.6 nmol/mL

Lauric Acid, C12:0

<1 year: 6-190 nmol/mL
1-17 years: 5-80 nmol/mL
> or = 18 years: 6-90 nmol/mL

Tetradecadienoic Acid, C14:2

<1 year: 0.3-6.5 nmol/mL
1-17 years: 0.2-5.8 nmol/mL
> or = 18 years: 0.8-5.0 nmol/mL

Myristoleic Acid, C14:1

<1 year: 1-46 nmol/mL
1-17 years: 1-31 nmol/mL
> or = 18 years: 3-64 nmol/mL

Myristic Acid, C14:0

<1 year: 30-320 nmol/mL
1-17 years: 40-290 nmol/mL
> or = 18 years: 30-450 nmol/mL

Hexadecadienoic Acid, C16:2
<1 year: 4-27 nmol/mL
1-17 years: 3-29 nmol/mL
> or =18 years: 10-48 nmol/mL

Hexadecenoic Acid, C16:1w9
<1 year: 21-69 nmol/mL
1-17 years: 24-82 nmol/mL
> or =18 years: 25-105 nmol/mL

Palmitoleic Acid, C16:1w7
<1 year: 20-1,020 nmol/mL
1-17 years: 100-670 nmol/mL
> or =18 years: 110-1,130 nmol/mL

Palmitic Acid, C16:0
<1 year: 720-3,120 nmol/mL
1-17 years: 960-3,460 nmol/mL
> or =18 years: 1,480-3,730 nmol/mL

Gamma-Linolenic Acid, C18:3w6
<1 year: 6-110 nmol/mL
1-17 years: 9-130 nmol/mL
> or =18 years: 16-150 nmol/mL

Alpha-Linolenic Acid, C18:3w3
<1 year: 10-190 nmol/mL
1-17 years: 20-120 nmol/mL
> or =18 years: 50-130 nmol/mL

Linoleic Acid, C18:2w6
< or =31 days: 350-2,660 nmol/mL
32 days-11 months: 1,000-3,300 nmol/mL
Test Definition: FAPCP
Fatty Acid Profile, Comprehensive, S

1-17 years: 1,600-3,500 nmol/mL
≥18 years: 2,270-3,850 nmol/mL

Oleic Acid, C18:1w9
<1 year: 250-3,500 nmol/mL
1-17 years: 350-3,500 nmol/mL
≥18 years: 650-3,500 nmol/mL

Vaccenic Acid, C18:1w7
<1 year: 140-720 nmol/mL
1-17 years: 320-900 nmol/mL
≥18 years: 280-740 nmol/mL

Stearic Acid, C18:0
<1 year: 270-1,140 nmol/mL
1-17 years: 280-1,170 nmol/mL
≥18 years: 590-1,170 nmol/mL

EPA, C20:5w3
<1 year: 2-60 nmol/mL
1-17 years: 8-90 nmol/mL
≥18 years: 14-100 nmol/mL

Arachidonic Acid, C20:4w6
<1 year: 110-1,110 nmol/mL
1-17 years: 350-1,030 nmol/mL
≥18 years: 520-1,490 nmol/mL

Mead Acid, C20:3w9
<31 days: 8-60 nmol/mL
32 days-11 months: 3-24 nmol/mL
≥1 year: 7-30 nmol/mL
Homo-Gamma-Linolenic Acid, C20:3w6
<1 year: 30-170 nmol/mL
1-17 years: 60-220 nmol/mL
> or =18 years: 50-250 nmol/mL

Arachidic Acid, C20:0
<1 year: 30-120 nmol/mL
1-17 years: 30-90 nmol/mL
> or =18 years: 50-90 nmol/mL

DHA, C22:6w3
<1 year: 10-220 nmol/mL
1-17 years: 30-160 nmol/mL
> or =18 years: 30-250 nmol/mL

DPA, C22:5w6
<1 year: 3-70 nmol/mL
1-17 years: 10-50 nmol/mL
> or =18 years: 10-70 nmol/mL

DPA, C22:5w3
<1 year: 6-110 nmol/mL
1-17 years: 30-270 nmol/mL
> or =18 years: 20-210 nmol/mL

DTA, C22:4w6
<1 year: 2-50 nmol/mL
1-17 years: 10-40 nmol/mL
> or =18 years: 10-80 nmol/mL

Docosenoic Acid, C22:1
<1 year: 2-20 nmol/mL
Test Definition: FAPCP
Fatty Acid Profile, Comprehensive,

> or =1 year: 4-13 nmol/mL

Docosanoic Acid, C22:0
0.0-96.3 nmol/mL

Nervonic Acid, C24:1
<1 year: 30-150 nmol/mL
1-17 years: 50-130 nmol/mL
> or =18 years: 60-100 nmol/mL

Tetracosanoic Acid, C24:0
0.0-91.4 nmol/mL

Hexacosenoic Acid, C26:1
<1 year: 0.2-2.1 nmol/mL
> or =1 year: 0.3-0.7 nmol/mL

Hexacosanoic Acid, C26:0
0.00-1.30 nmol/mL

Pristanic Acid, C15:0(CH3)4
< or =4 months: 0.00-0.60 nmol/mL
5-8 months: 0.00-0.84 nmol/mL
9-12 months: 0.00-0.77 nmol/mL
13-23 months: 0.00-1.47 nmol/mL
> or =2 years: 0.00-2.98 nmol/mL

Phytanic Acid, C16:0(CH3)4
< or =4 months: 0.00-5.28 nmol/mL
5-8 months: 0.00-5.70 nmol/mL
9-12 months: 0.00-4.40 nmol/mL
13-23 months: 0.00-8.62 nmol/mL
> or =2 years: 0.00-9.88 nmol/mL
Triene/Tetraene Ratio
< or =31 days: 0.017-0.083
32 days-17 years: 0.013-0.050
> or =18 years: 0.010-0.038

Total Saturated Acid
<1 year: 1.2-4.6 mmol/L
1-17 years: 1.4-4.9 mmol/L
> or =18 years: 2.5-5.5 mmol/L

Total Monounsaturated Acid
<1 year: 0.3-4.6 mmol/L
1-17 years: 0.5-4.4 mmol/L
> or =18 years: 1.3-5.8 mmol/L

Total Polyunsaturated Acid
<1 year: 1.1-4.9 mmol/L
1-17 years: 1.7-5.3 mmol/L
> or =18 years: 3.2-5.8 mmol/L

Total w3
<1 year: 0.0-0.4 mmol/L
1-17 years: 0.1-0.5 mmol/L
> or =18 years: 0.2-0.5 mmol/L

Total w6
<1 year: 0.9-4.4 mmol/L
1-17 years: 1.6-4.7 mmol/L
> or =18 years: 3.0-5.4 mmol/L

Total Fatty Acids
<1 year: 3.3-14.0 mmol/L
Interpretation

An increased triene:tetraene ratio is consistent with essential fatty acid deficiency.

Fatty acid oxidation disorders are recognized on the basis of disease-specific patterns that are correlated to the results of other investigations in plasma (carnitine, acylcarnitines) and urine (organic acids, acylglycines).

Increased concentrations of serum very long-chain fatty acids (VLCFA) C24:0 and C26:0 are seen in peroxisomal disorders, X-linked adrenoleukodystrophy, adrenomyeloneuropathy, and Zellweger syndrome (cerebrohepatorenal syndrome).

Increased concentrations of serum phytanic acid (along with normal pristanic acid concentrations) are seen in the Refsum disease (phytanase deficiency). Serum phytanic acid concentration also may be increased in other peroxisomal disorders and, when combined with the VLCFA, pristanoic acid and pipecolic acid allow differential diagnosis of peroxisomal disorders.

Cautions

For nutritional assessment, a 12- to 14-hour fast is required; however, infants or persons suspected of having a fatty acid oxidation disorder should not fast before testing owing to the possibility of acute metabolic decompensation. Instead, collect the specimen after the longest fast possible, just before feeding. In the case of a patient on total parenteral nutrition (TPN), specimen can be drawn as normal.

Clinical Reference


Performance

Method Description

Quantitation of fatty acids of specific chain lengths is performed as follows: a 2-step, acid-base hydrolysis is followed by hexane extraction and derivatization with pentafluorobenzyl bromide. Separation and detection are accomplished by capillary gas chromatography electron-capture negative ion-mass spectrometry. Quantitation is based on analysis in the selected ion-monitoring mode by using 13 stable isotope-labeled internal standards. (Lagerstedt SA, Hinrichs DR, Batt SM, et al: Quantitative determination of plasma C8-C26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. Mol Genet Metab 2001;73:38-45)

PDF Report

No

Day(s) and Time(s) Test Performed

Monday through Friday; 7 a.m.

Analytic Time

Document generated June 10, 2020 at 2:50am CDT
Test Definition: FAPCP
Fatty Acid Profile, Comprehensive,S

4 days (not reported on Saturdays or Sundays)

Maximum Laboratory Time
7 days

Specimen Retention Time
2 months

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
82542

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAPCP</td>
<td>Fatty Acid Profile, Comprehensive,S</td>
<td>43674-1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>16965</td>
<td>Octanoic Acid, C8:0</td>
<td>35145-2</td>
</tr>
<tr>
<td>16966</td>
<td>Decenoic Acid, C10:1</td>
<td>35147-8</td>
</tr>
<tr>
<td>16967</td>
<td>Decanoic Acid, C10:0</td>
<td>35146-0</td>
</tr>
<tr>
<td>16968</td>
<td>Lauroleic Acid, C12:1</td>
<td>35151-0</td>
</tr>
<tr>
<td>16969</td>
<td>Lauric Acid, C12:0</td>
<td>35150-2</td>
</tr>
<tr>
<td>16970</td>
<td>Tetradecadienoic Acid, C14:2</td>
<td>35148-6</td>
</tr>
<tr>
<td>16971</td>
<td>Myristoleic Acid, C14:1</td>
<td>35158-5</td>
</tr>
<tr>
<td>16972</td>
<td>Myristic Acid, C14:0</td>
<td>35157-7</td>
</tr>
<tr>
<td>16973</td>
<td>Hexadecadienoic Acid, C16:2</td>
<td>35154-4</td>
</tr>
<tr>
<td>16974</td>
<td>Hexadecenoic Acid, C16:1w9</td>
<td>35155-1</td>
</tr>
<tr>
<td>16975</td>
<td>Palmitoleic Acid, C16:1w7</td>
<td>35162-7</td>
</tr>
<tr>
<td>16976</td>
<td>Palmitic Acid, C16:0</td>
<td>35161-9</td>
</tr>
<tr>
<td>16977</td>
<td>g-Linolenic Acid, C18:3w6</td>
<td>35163-5</td>
</tr>
<tr>
<td>Result ID</td>
<td>Test Result Name</td>
<td>Result LOINC Value</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>16978</td>
<td>a-Linolenic Acid, C18:3w3</td>
<td>35164-3</td>
</tr>
<tr>
<td>16979</td>
<td>Linoleic Acid, C18:2w6</td>
<td>35165-0</td>
</tr>
<tr>
<td>16980</td>
<td>Oleic Acid, C18:1w9</td>
<td>35166-8</td>
</tr>
<tr>
<td>16981</td>
<td>Vaccenic Acid, C18:1w7</td>
<td>35167-6</td>
</tr>
<tr>
<td>16982</td>
<td>Stearic Acid, C18:0</td>
<td>35149-4</td>
</tr>
<tr>
<td>16983</td>
<td>EPA, C20:5w3</td>
<td>35173-4</td>
</tr>
<tr>
<td>16984</td>
<td>Arachidonic Acid, C20:4w6</td>
<td>35168-4</td>
</tr>
<tr>
<td>16985</td>
<td>Mead Acid, C20:3w9</td>
<td>35172-6</td>
</tr>
<tr>
<td>16986</td>
<td>h-g-Linolenic Acid, C20:3w6</td>
<td>35171-8</td>
</tr>
<tr>
<td>16987</td>
<td>Arachidic Acid, C20:0</td>
<td>35169-2</td>
</tr>
<tr>
<td>16988</td>
<td>DHA, C22:6w3</td>
<td>35174-2</td>
</tr>
<tr>
<td>16989</td>
<td>DPA, C22:5w6</td>
<td>35181-7</td>
</tr>
<tr>
<td>16990</td>
<td>DPA, C22:5w3</td>
<td>35180-9</td>
</tr>
<tr>
<td>16991</td>
<td>DTA, C22:4w6</td>
<td>35182-5</td>
</tr>
<tr>
<td>16992</td>
<td>Docosenoic Acid, C22:1</td>
<td>35160-1</td>
</tr>
<tr>
<td>16993</td>
<td>Docosanoic Acid, C22:0</td>
<td>30194-5</td>
</tr>
<tr>
<td>16994</td>
<td>Nervonic Acid, C24:1w9</td>
<td>35170-0</td>
</tr>
<tr>
<td>16995</td>
<td>Tetracosanoic Acid, C24:0</td>
<td>30195-2</td>
</tr>
<tr>
<td>16996</td>
<td>Hexacosenoic Acid, C26:1</td>
<td>33036-5</td>
</tr>
<tr>
<td>16997</td>
<td>Hexacosanoic Acid, C26:0</td>
<td>30197-8</td>
</tr>
<tr>
<td>16998</td>
<td>Pristanic Acid, C15:0(CH3)4</td>
<td>22761-1</td>
</tr>
<tr>
<td>16999</td>
<td>Phytanic Acid, C16:0(CH3)4</td>
<td>22671-2</td>
</tr>
<tr>
<td>17000</td>
<td>Triene Tetraene Ratio</td>
<td>35411-8</td>
</tr>
<tr>
<td>17001</td>
<td>Total Saturated</td>
<td>35175-9</td>
</tr>
<tr>
<td>17002</td>
<td>Total Monounsaturated</td>
<td>35176-7</td>
</tr>
<tr>
<td>17003</td>
<td>Total Polyunsaturated</td>
<td>35177-5</td>
</tr>
<tr>
<td>17004</td>
<td>Total w3</td>
<td>35178-3</td>
</tr>
<tr>
<td>17005</td>
<td>Total w6</td>
<td>35179-1</td>
</tr>
<tr>
<td>17006</td>
<td>Total Fatty Acids</td>
<td>24461-6</td>
</tr>
<tr>
<td>17056</td>
<td>Interpretation</td>
<td>59462-2</td>
</tr>
</tbody>
</table>